• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高通量筛选揭示脊髓性肌萎缩症患者的新突变。

High-throughput screening reveals novel mutations in spinal muscular atrophy patients.

机构信息

Department of Pediatric, Tianjin Children's Hospital, Tianjin, 300134, China.

Graduate School, Tianjin Medical University, Tianjin, 300070, China.

出版信息

Ital J Pediatr. 2020 Nov 4;46(1):166. doi: 10.1186/s13052-020-00925-1.

DOI:10.1186/s13052-020-00925-1
PMID:33148303
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7641840/
Abstract

BACKGROUND

Spinal muscular atrophy (SMA) is an autosomal recessive hereditary disease associated with severe muscle atrophy and weakness in the limbs and trunk. The discovery of mutated genes is helpful in diagnosis and treatment for SMA.

METHODS

Eighty-three whole blood samples were collected from 28 core families of clinically suspected SMA, and multiplex ligation probe amplification (MLPA) was performed. Afterwards, the complete gene sequence of SMN1 gene was detected. Furthermore, 20 SMA patients were selected from the 28 probands, and 5 non SMA children as controls. The Life Technologies SOLiD™ technology with mate-pair chemistry was utilized to conduct the whole exome high-throughput sequencing.

RESULTS

Twenty-two probands were SMA patients, 3 probands carriers, and 3 probands normal individuals. Moreover, 2 parents from 2 SMA families were with 3 SMN1 exon7 copies. Six SMN1 single nucleotide variants (SNVs) were identified in the 83 samples, and c.[84C > T], c.[271C > T], c.[-39A > G] and g.[70240639G > C] were novel. Compared with control group, 9102 mutation were selected out in SMA patients. SPTA1 mutation c.[-41_-40insCTCT], FUT5 SNV c.[1001A > G], and MCCC2 SNV c.[-117A > G] were the 3 most frequent mutations in SMA group (95, 85 and 75%, respectively).

CONCLUSIONS

We identified some mutations in both SMN1 and other genes, and c.[271C > T], c.[-41_-40insCTCT], c.[1001A > G] and c.[-117A > G] might be associated with the onset of SMA.

摘要

背景

脊髓性肌萎缩症(SMA)是一种常染色体隐性遗传性疾病,与四肢和躯干严重的肌肉萎缩和无力有关。突变基因的发现有助于 SMA 的诊断和治疗。

方法

采集 28 个临床疑似 SMA 的核心家系的 83 例全血样本,进行多重连接探针扩增(MLPA),然后检测 SMN1 基因的完整基因序列。从 28 个先证者中选择 20 个 SMA 患者和 5 个非 SMA 儿童作为对照。利用 Life Technologies SOLiD™ 技术与 mate-pair 化学进行全外显子高通量测序。

结果

22 个先证者为 SMA 患者,3 个先证者为携带者,3 个先证者为正常个体。此外,2 个 SMA 家系的 2 个父母均有 3 个 SMN1 外显子 7 个拷贝。在 83 个样本中鉴定出 6 个 SMN1 单核苷酸变异(SNV),c.[84C > T]、c.[271C > T]、c.[-39A > G]和 g.[70240639G > C]为新发现的变异。与对照组相比,在 SMA 患者中选择出 9102 个突变。SMA 组最常见的突变有 SPTA1 基因 c.[-41_-40insCTCT]、FUT5 基因 SNV c.[1001A > G]和 MCCC2 基因 SNV c.[-117A > G],分别为 95%、85%和 75%。

结论

我们在 SMN1 和其他基因中发现了一些突变,c.[271C > T]、c.[-41_-40insCTCT]、c.[1001A > G]和 c.[-117A > G]可能与 SMA 的发病有关。

相似文献

1
High-throughput screening reveals novel mutations in spinal muscular atrophy patients.高通量筛选揭示脊髓性肌萎缩症患者的新突变。
Ital J Pediatr. 2020 Nov 4;46(1):166. doi: 10.1186/s13052-020-00925-1.
2
Discovery of specific mutations in spinal muscular atrophy patients by next-generation sequencing.通过新一代测序技术发现脊髓性肌萎缩症患者的特定突变。
Neurol Sci. 2021 May;42(5):1827-1833. doi: 10.1007/s10072-020-04697-8. Epub 2020 Sep 7.
3
Spinal muscular atrophy carriers with two SMN1 copies.具有两个SMN1拷贝的脊髓性肌萎缩症携带者。
Brain Dev. 2017 Nov;39(10):851-860. doi: 10.1016/j.braindev.2017.06.002. Epub 2017 Jul 1.
4
Optimized MLPA workflow for spinal muscular atrophy diagnosis: identification of a novel variant, NC_000005.10:g.(70919941_70927324)del in isolated exon 1 of SMN1 gene through long-range PCR.用于脊髓性肌萎缩症诊断的优化MLPA工作流程:通过长距离PCR在SMN1基因的孤立外显子1中鉴定出一种新变体,NC_000005.10:g.(70919941_70927324)del
BMC Neurol. 2024 Mar 11;24(1):93. doi: 10.1186/s12883-024-03592-5.
5
Evaluating the clinical efficacy of a long-read sequencing-based approach for carrier screening of spinal muscular atrophy.评估基于长读测序的脊髓性肌萎缩症携带者筛查方法的临床疗效。
Hum Genomics. 2024 Sep 29;18(1):110. doi: 10.1186/s40246-024-00676-8.
6
Incorporating Spinal Muscular Atrophy Analysis by Next-Generation Sequencing into a Comprehensive Multigene Panel for Neuromuscular Disorders.将下一代测序的脊髓性肌萎缩症分析纳入神经肌肉疾病的综合多基因panel 中。
Genet Test Mol Biomarkers. 2020 Oct;24(10):616-624. doi: 10.1089/gtmb.2019.0282. Epub 2020 Jul 23.
7
Diagnosis of Spinal Muscular Atrophy: A Simple Method for Quantifying the Relative Amount of Survival Motor Neuron Gene 1/2 Using Sanger DNA Sequencing.脊髓性肌萎缩症的诊断:使用 Sanger DNA 测序定量存活运动神经元基因 1/2 相对含量的简单方法。
Chin Med J (Engl). 2018 Dec 20;131(24):2921-2929. doi: 10.4103/0366-6999.247198.
8
[Mutation analysis of SMN1 gene in patients with spinal muscular atrophy].[脊髓性肌萎缩症患者SMN1基因的突变分析]
Zhonghua Er Ke Za Zhi. 2011 Jun;49(6):411-5.
9
Comprehensive Mutation Analysis and Report of 12 Novel Mutations in a Cohort of Patients with Spinal Muscular Atrophy in Iran.伊朗脊髓性肌萎缩症患者队列中 12 种新突变的全面突变分析与报告。
J Mol Neurosci. 2021 Nov;71(11):2281-2298. doi: 10.1007/s12031-020-01789-0. Epub 2021 Jan 22.
10
Mutation analysis of 419 family and prenatal diagnosis of 339 cases of spinal muscular atrophy in China.在中国,对 419 个家系进行突变分析及对 339 例脊髓性肌萎缩症进行产前诊断。
BMC Med Genet. 2020 Jun 18;21(1):133. doi: 10.1186/s12881-020-01069-z.

本文引用的文献

1
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?脊髓性肌萎缩症的诊断之旅:是否仍充满曲折?
PLoS One. 2020 Mar 23;15(3):e0230677. doi: 10.1371/journal.pone.0230677. eCollection 2020.
2
Transmission characteristics of SMN from 227 spinal muscular atrophy core families in China.中国 227 个脊髓性肌萎缩症核心家系中 SMN 的传递特征。
J Hum Genet. 2020 May;65(5):469-473. doi: 10.1038/s10038-020-0730-1. Epub 2020 Feb 13.
3
Analysis of , , and as potential disease severity modifiers in spinal muscular atrophy.分析、和作为脊髓性肌萎缩症潜在疾病严重程度调节因子的情况。
Neurol Genet. 2019 Jan 3;6(1):e386. doi: 10.1212/NXG.0000000000000386. eCollection 2020 Feb.
4
Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype.对 SMA 患者的 SMN2 基因进行完整测序可检测到 SMN 基因缺失连接点以及改变 SMA 表型的 SMN2 基因变异。
Hum Genet. 2019 Mar;138(3):241-256. doi: 10.1007/s00439-019-01983-0. Epub 2019 Feb 20.
5
Noninvasive molecular diagnosis of craniopharyngioma with MRI-based radiomics approach.基于MRI的影像组学方法对颅咽管瘤进行无创分子诊断
BMC Neurol. 2019 Jan 7;19(1):6. doi: 10.1186/s12883-018-1216-z.
6
Batten disease: biochemical and molecular characterization revealing novel PPT1 and TPP1 gene mutations in Indian patients.巴顿病:生化与分子特征揭示印度患者中新型PPT1和TPP1基因突变
BMC Neurol. 2018 Dec 12;18(1):203. doi: 10.1186/s12883-018-1206-1.
7
Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases.重新探讨 SMA 类型与 SMN2 拷贝数的相关性:对 625 例无关西班牙患者的分析及 2834 例报道病例的综合分析。
Neuromuscul Disord. 2018 Mar;28(3):208-215. doi: 10.1016/j.nmd.2018.01.003. Epub 2018 Jan 11.
8
Spinal muscular atrophy carriers with two SMN1 copies.具有两个SMN1拷贝的脊髓性肌萎缩症携带者。
Brain Dev. 2017 Nov;39(10):851-860. doi: 10.1016/j.braindev.2017.06.002. Epub 2017 Jul 1.
9
A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy.SMN2基因第6内含子中的A-44G转换对脊髓性肌萎缩症患者具有保护作用。
Hum Mol Genet. 2017 Jul 15;26(14):2768-2780. doi: 10.1093/hmg/ddx166.
10
ISS-N1 makes the First FDA-approved Drug for Spinal Muscular Atrophy.ISS-N1成为首个获美国食品药品监督管理局批准用于治疗脊髓性肌萎缩症的药物。
Transl Neurosci. 2017 Jan 26;8:1-6. doi: 10.1515/tnsci-2017-0001. eCollection 2017 Jan.